Pajouheshnia R, Peelen LM, Moons KGM, Reitsma JB, Groenwold RHH. Accounting for treatment use when validating a prognostic model: a simulation study. BMC Med Res Methodol. 2017 Jul 14;17(1):103. doi: 10.1186/s12874-017-0375-8
Pajouheshnia R, Pestman WR, Teerenstra S, Groenwold RHH. A computational approach to compare regression modelling strategies in prediction research. BMC Med Res Methodol. 2016 Aug 25;16(1):107. doi: 10.1186/s12874-016-0209-0
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Le HV, Poole C, Brookhart MA, Schoenbach VJ, Beach KJ, Layton JB, Stumer T. Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. BMC Med Res Methodol. 2013 Nov 19;13:142. doi: 10.1186/1471-2288-13-142
Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, Solomon DH, Kim SY, Rothman KJ, Avorn J. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26;12(11):180.
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Gili M, Luciano JV, Bauzá N, Aguado J, Serrano MJ, Armengol S, Roca M. Psychometric properties of the IDS-SR30 for the assessment of depressive symptoms in Spanish population. BMC Med Res Methodol. 2011 Sep;21(11):131.
Luciano JV, Ayuso-Mateos JL, Aguado J, Fernandez A, Serrano-Blanco A, Roca M, Haro JM. The 12-item World Health Organization Disability Assessment Schedule II (WHO-DAS II): a nonparametric item response analysis. BMC Med Res Methodol. 2010 May 20;10(45). doi: 10.1186/1471-2288-10-45.